Department of Medical Laboratory, Central Hospital of Wuhan, Wuhan 430014, China.
Eur J Med Res. 2013 Nov 14;18(1):44. doi: 10.1186/2047-783X-18-44.
Primary hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. However, the molecular pathogenesis of HCC is not well-understood, and the prognosis for patients with HCC remains very poor.
To disclose detailed genetic mechanisms in hepatocellular carcinoma (HCC) with a view toward development of novel therapeutic targets, we analyzed expression profiles HCCs and their corresponding noncancerous tissues by using bioinformatics method.
In this paper, we report the identification of genes whose expression has been altered and the changed bio-pathways during hepatocarcinogenesis. Hepatoma cells infect intracellular and intercellular signal transduction through Focal adhesion and cause abnormal expression of important intracellular signaling pathway. In addition, it is worth mentioning that some small molecules still restored to the state similar to normal cells, such as bambuterol and lovastatin. This member gene set would serve as a pool of lead gene targets for the identification and development of novel diagnostic and therapeutic biomarkers to greatly improve the clinical management of HCC patients with different risks of recurrence after curative partial hepatectomy.
The study has great significance for gene therapy and pharmacotherapy and provides a new treatment entry point and a potential new clinical drug for HCC patients.
原发性肝细胞癌(HCC)是世界上最常见的恶性肿瘤之一。然而,HCC 的分子发病机制尚不清楚,HCC 患者的预后仍然很差。
为了揭示肝癌(HCC)的详细遗传机制,以期开发新的治疗靶点,我们使用生物信息学方法分析了 HCC 及其相应非癌组织的表达谱。
在本文中,我们报告了在肝癌发生过程中鉴定到的表达发生改变的基因和改变的生物途径。肝癌细胞通过黏附和细胞间信号转导感染细胞内和细胞间信号转导,导致重要的细胞内信号通路异常表达。此外,值得一提的是,一些小分子化合物如巴氨西林和洛伐他汀仍恢复到类似于正常细胞的状态。这个基因集将作为一个潜在的治疗靶点,用于识别和开发新的诊断和治疗生物标志物,以极大地改善不同复发风险的 HCC 患者在根治性部分肝切除术后的临床管理。
该研究对基因治疗和药物治疗具有重要意义,为 HCC 患者提供了新的治疗切入点和潜在的临床药物。